VIB-RUG Department of Molecular Biomedical Research

Molecular ImmunoBiotechnology Unit

 

 

 

 

 

 

 

 

The Tribody model:

The ideal antibody manifold depends on your application. But suppose you want a highly specific binding, since you like to target some active compounds to a tumor cell. Then you would like a molecule that does not remains in the bloodstream for too long, but also is not cleared in a half hour since this would not allow for sufficient time to accumulate to the target cell.

bulletYou need an antibody lacking the Fc tail
bulletYou need an intermediate weight molecule, to avoid clearance in the kidney glomerula.

Clinical Useful BsAb should:

bullet

have a highly selective tumor binding with high affinity.

bullet

should bind effector cells monovalent and only be cross linked when encountering cell-bound tumor antigen, they should thus not contain an Fc-portion

bullet

should promote selective in situ tumor inflammation by relevant leukocyte population

bullet

should be of human origin

bullet

should be small enough to penetrate tumors, but large enough to remain for a reasonable time in circulation

If you would like to combine functions with the antibody, or would like the controlled heterodimerization of bispecific antibodies, with precise control on the multiplicity of binding of each component....

click

Rotating structure of a Tribody molecule 

[Antibodies] [Immunotherapy] [BsAb] [Tribody]

Home

Contact

Research projects

Publications

After eight

Check out 

links to:

MABs on the market
Antibody Companies
Immune Therapy Companies
Custom protein expression and purification
Biotech in Flanders
Flanders Universities
Flanders Biotech Policy

                  

2002 Webmaster